Neutralizing Antibody Testing via ACE2 Receptor Blocking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting neutralizing antibodies to SARS-CoV-2 in convalescent plasma lack accuracy, leading to inconsistent administration of therapeutic plasma to patients, as they do not reliably measure the abundance or neutralizing capacity of antibodies, which is crucial for clinical outcomes.
Innovation Solution
The IMMUNOPASS diagnostic method involves a lateral flow test using a combination of SARS-CoV-2 antigen coated colored particles and a modified human ACE2 protein receptor to detect neutralizing antibodies by blocking the interaction of the virus with human cells expressing ACE2, providing a semi-quantitative measurement of neutralizing antibody levels in plasma or serum.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional serology tests are used to detect antibodies in convalescent plasma, then the testing process is simple and quick, but the tests cannot reliably measure neutralizing antibody levels or capacity
Solution Approach 1:
The patent introduces an intermediary system using ACE2-expressing cells as a mediator between the antibody sample and the detection system. The neutralizing antibodies in the sample interact with the viral antigen in the presence of ACE2 cells, and the effect on cell viability or function is then detected. This intermediary approach enables precise measurement of neutralizing capacity while maintaining a manageable test structure.
Solution Approach 2:
The patent replaces conventional mechanical/chemical assay methods with a biological system-based detection approach. Instead of using complex mechanical mixing or chemical reactions to measure antibody neutralization, the system uses living cells (ACE2-expressing cells) to perform the neutralization function, with the cellular response serving as the detection signal. This substitution enables more physiologically relevant and accurate measurements.
2Reliability
If neutralizing antibody testing is not performed on convalescent plasma, then the plasma can be rapidly made available for treatment, but the therapeutic efficacy cannot be ensured
Solution Approach 1:
The patent implements preliminary testing of convalescent plasma donors using the neutralizing antibody assay before the plasma is collected and distributed. By performing the neutralization test in advance on donor samples, the system identifies high-titer plasma units that are guaranteed to be therapeutically effective. This preliminary action ensures reliability while allowing rapid deployment of pre-validated plasma stocks when needed.
Solution Approach 2:
The patent applies partial testing rather than testing every single plasma unit in its entirety. Instead of fully characterizing every plasma donation, the system performs neutralizing antibody testing on representative samples from donor pools, and uses this partial information to make decisions about plasma allocation and distribution. This approach balances thoroughness with speed.
3Ease of operation
If high titers of neutralizing antibodies are produced in some patients, then those patients have strong immune response, but they receive more neutralizing antibodies than needed while other patients don't get enough
Solution Approach 1:
The patent implements a feedback system where the neutralizing antibody titers of plasma donors are measured and this information feeds back into the plasma distribution decision-making process. The quantitative neutralization data provides feedback on the actual therapeutic content of each plasma unit, enabling standardized dosing based on measured neutralizing capacity rather than arbitrary volume-based administration. This feedback loop ensures each patient receives an appropriate, standardized amount of neutralizing activity.
Solution Approach 2:
The patent changes the critical parameter for plasma characterization from simple antibody presence/absence or total antibody titer to functional neutralizing antibody capacity. By measuring the actual neutralization effect rather than just antibody quantity, the system captures the clinically relevant parameter that determines therapeutic efficacy. This parameter change enables standardized dosing based on functional activity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach accurately measures neutralizing antibody levels, ensuring that convalescent plasma with sufficient neutralizing capacity is administered to patients and potentially limiting virus transmission and re-infection, while also serving as a companion diagnostic for vaccine efficacy.
Implementation Method 1
the conjugate pad comprises a viral-ACE2-binding protein coupled to a label... that block interaction of the virus with human cells expressing ACE2
Data Source
AI summary
Provided herein are diagnostic methods, devices and kits for detecting neutralizing antibodies to SARS-CoV-2.